Jim Simons Amgen Inc Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Amgen Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 167,245 shares of AMGN stock, worth $57.1 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

167,245

Previous 277,300 39.69%

Holding current value

$57.1 Million

Previous $77.4 Million 39.04%

% of portfolio

0.07%

Previous 0.11%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$271.18 - $309.22 $29.8 Million - $34 Million	-110,055 Reduced 39.69%	167,245 $47.2 Million
Q2 2025 Aug 13, 2025	BUY	$262.28 - $309.85 $42.7 Million - $50.5 Million	162,900 Added 142.4%	277,300 $77.4 Million
Q1 2025 May 14, 2025	BUY	$258.59 - $327.36 $11.7 Million - $14.8 Million	45,355 Added 65.69%	114,400 $35.6 Million
Q4 2024 Feb 13, 2025	BUY	$258.78 - $328.31 $17.9 Million - $22.7 Million	69,045 New	69,045 $18 Million
Q2 2024 Aug 09, 2024	SELL	$262.75 - $319.31 $776,426 - $943,561	-2,955 Reduced 5.35%	52,245 $16.3 Million

Q1 2024 May 13, 2024	SELL	$268.87 - $324.56 $5.73 Million - $6.91 Million	-21,300 Reduced 27.84%	55,200 $15.7 Million
Q4 2023 Feb 13, 2024	BUY	$255.7 - $288.46 $3.12 Million - $3.52 Million	12,200 Added 18.97%	76,500 $22 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $43.1 Million - $53.5 Million	-197,045 Reduced 75.4%	64,300 $17.3 Million
Q2 2023 Aug 11, 2023	SELL	$214.27 - $253.37 $185 Million - $218 Million	-861,300 Reduced 76.72%	261,345 $58 Million
Q1 2023 May 12, 2023	SELL	$225.79 - $275.2 $109 Million - $133 Million	-484,600 Reduced 30.15%	1,122,645 $271 Million
Q4 2022 Feb 13, 2023	BUY	$229.03 - $291.01 $223 Million - $283 Million	974,000 Added 153.81%	1,607,245 $422 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $181 Million - $204 Million	-806,500 Reduced 56.02%	633,245 $143 Million
Q2 2022 Aug 12, 2022	BUY	$230.71 - $256.74 $245 Million - $272 Million	1,060,200 Added 279.33%	1,439,745 $350 Million
Q1 2022 May 13, 2022	SELL	$219.27 - $242.57 $158 Million - $175 Million	-722,308 Reduced 65.55%	379,545 $91.8 Million
Q4 2021 Feb 11, 2022	BUY	$198.88 - $227.6 $189 Million - $216 Million	950,008 Added 625.64%	1,101,853 $248 Million
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $32.2 Million - $37.8 Million	151,845 New	151,845 $32.3 Million
Q2 2021 Aug 13, 2021	SELL	$233.58 - $259.14 $280,296 - $310,968	-1,200 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$221.91 - $258.6 $36.9 Million - $43 Million	-166,445 Reduced 99.28%	1,200 $299,000
Q4 2020 Feb 10, 2021	SELL	$216.38 - $257.67 $87.8 Million - $105 Million	-405,639 Reduced 70.76%	167,645 $38.5 Million
Q3 2020 Nov 13, 2020	SELL	$234.65 - $260.95 $244 Million - $271 Million	-1,038,330 Reduced 64.43%	573,284 $146 Million
Q2 2020 Aug 13, 2020	SELL	$197.81 - $242.74 $423 Million - $519 Million	-2,138,389 Reduced 57.02%	1,611,614 $380 Million
Q1 2020 May 14, 2020	BUY	$182.24 - $241.7 $108 Million - $143 Million	590,465 Added 18.69%	3,750,003 $760 Million
Q4 2019 Feb 13, 2020	SELL	$189.21 - $243.2 $94.3 Million - $121 Million	-498,548 Reduced 13.63%	3,159,538 $762 Million
Q3 2019 Nov 13, 2019	BUY	$174.11 - $208.62 $121 Million - $145 Million	694,848 Added 23.45%	3,658,086 $708 Million
Q2 2019 Aug 12, 2019	SELL	$166.7 - $195.41 $90.9 Million - $107 Million	-545,345 Reduced 15.54%	2,963,238 $546 Million
Q1 2019 May 14, 2019	SELL	$180.87 - $203.88 $12.7 Million - $14.3 Million	-70,017 Reduced 1.96%	3,508,583 $667 Million
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $638 Million - $745 Million	3,578,600 New	3,578,600 $697 Million

Others Institutions Holding AMGN

# of Institutions

3,273

Shares Held

428M

Call Options Held

6.11M

Put Options Held

5.85M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $183B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account